Neurocrine Bio. (NBIX) PT Raised to $119 at Mizuho Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $164.85 +13.42%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Mizuho Securities analyst Vamil Divan raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $119.00 (from $117.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Cantor Fitzgerald Reiterates Overweight Rating on Neurocrine Bio. (NBIX)
- Neurocrine Bio. (NBIX) PT Raised to $220 at Canaccord
- Neurocrine Bio. (NBIX) PT Raised to $190 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
